Received: September 26, 2020 Accepted: September 30, 2020 Published: September 30, 2020
Current evidence indicate an inextricable link between coronavirus disease 2019 (COVID‑19) and cardiovascular diseases (CVDs). Age, obesity and male sex are potent shared risk factors which link the two conditions. Although severe acute respiratory syndrome‑coronavirus 2 (SARS‑CoV‑2) principally affects the lungs, about two thirds of patients demonstrate some cardiac involvement including new‑onset cardiac dysfunction during the course of the illness. As outlined in this video, cardiovascular manifestations of COVID‑19 are complex with patients presenting with one or more of the following: myocarditis, acute myocardial infarction, stroke, cardiomyopathy, heart failure, arrhythmias, acute pericarditis, and venous thromboembolism. Preexisting CVDs such as hypertension and coronary heart disease make people more vulnerable to SARS‑CoV‑2 infection. Preexisting CVDs also adversely impact clinical outcomes of COVID-19. Adjusting health service delivery to effectively meet the cardiac and stroke care needs of people during the pandemic remains a challenge. Doctors caring for COVID‑19 patients need to be aware of the potential cardiovascular side effects of various therapies used for treating SARS‑CoV‑2 infection, including chloroquine/hydroxychloroquine and azithromycin. Today, nine months after COVID-19 emerged, science has given us a better understanding of COVID-19. Further research is essential to gain an in-depth insight into the underlying mechanisms that shape the close interplay between SARS‑CoV‑2 infection and CVDs.